
Foresee Pharmaceuticals Announces First Patient Dosed In The Phase 2 WINDWARD Study Of The ALDH2 Activator Mirivadelgat ...
(MENAFN- PR Newswire) The WINDWARD study is a multinational, double-blind, 3-arm Phase 2 study to evaluate the safety and efficacy of mirivadelgat in adult subjects with PH-ILD. Mirivadelgat is a first-in-class oral small molecule with a novel mechanism of …